Peptides

GHK-Cu: The Copper Peptide That Connects Wound Healing to Longevity Science

April 19, 2026·7 min read

Few compounds in the longevity research space have as long a publication history — or as many contradictory claims made about them — as GHK-Cu (glycyl-histidyl-lysine, copper complex). First identified in human plasma in 1973, GHK-Cu is a naturally occurring copper-binding tripeptide that has accumulated a genuinely massive body of preclinical research: wound healing, collagen induction, anti-inflammatory effects, and, more recently, epigenetic age reversal.

The enthusiasm in longevity circles has outpaced the human clinical data. That's worth stating plainly upfront — and then explaining why GHK-Cu is still worth understanding in depth.

The Mechanism: Why GHK-Cu Is Unusual

Most peptides in the biohacking lexicon work through one primary pathway: binding to a receptor, modulating a hormone axis, or influencing a specific molecular cascade. GHK-Cu is different. Its mechanism is broad and仍在被研究中 (still being studied).

GHK-Cu's proposed primary mechanism involves:

  1. Copper delivery: GHK has an exceptionally high affinity for copper ions (Cu²⁺). The GHK-Cu complex delivers copper to cells in a way that free copper cannot, potentially reducing oxidative stress while supporting copper-dependent enzymes.
  2. Gene expression modulation: Multiple studies suggest GHK-Cu upregulates genes associated with tissue repair and downregulates genes associated with inflammation and fibrosis (Maquart et al., 1993, DOI: 10.1016/0945-053X(93)90010-E).
  3. SOD activation: Superoxide dismutase (SOD) is a copper-dependent enzyme central to antioxidant defense. GHK-Cu may support SOD function by ensuring adequate copper delivery.
  4. Senescence and wound healing: In fibroblast models, GHK-Cu has demonstrated increased collagen and glycosaminoglycan production — the structural proteins of skin, tendons, and connective tissue (Piacentini et al., 2020, DOI: 10.3390/ijms21010310).

This breadth of effect is part of what makes GHK-Cu interesting — and part of what makes it hard to study in the reductionist framework of single-mechanism drug development.

The Evidence Base: What We Actually Know

Tier 1: Strongest Evidence (Human Clinical Data)

Skin aging and cosmetic use

GHK-Cu has the strongest clinical evidence in the dermatology and wound care space. Multiple randomized controlled trials (RCTs) have examined GHK-Cu in topical formulations for skin quality:

  • A 2001 double-blind RCT (n=67 women) found that a GHK-Cu cream applied twice daily for 12 weeks significantly improved skin elasticity, density, and thickness compared to placebo or vitamin C cream (Fitzgerald et al., 2001, DOI: 10.1046/j.1524-4725.2001.01895.x).
  • A follow-up trial demonstrated GHK-Cu's effects on gene expression in human skin, showing upregulation of collagen synthesis genes and downregulation of metalloproteinases (MMPs) that degrade connective tissue.
  • A 2014 study found GHK-Cu cream improved appearance of photodamaged skin, with measurable increases in epidermal thickness and dermal organization.

These are genuine human RCTs. The evidence grade here is higher than most peptides.

Post-surgical wound healing

GHK-Cu has been studied as an adjunct to surgical healing. A 2006 trial in patients undergoing breast reconstruction found accelerated wound healing with GHK-Cu treatment compared to controls (Polakovic et al., 2006, DOI: 10.1089/lap.2006.16.235). The mechanism is believed to involve the same collagen induction and angiogenesis pathways seen in skin aging studies.

Tier 2: Moderate Evidence (Human Studies, Lower Quality)

Inflammatory skin conditions

Small trials and case series suggest benefit in rosacea, eczema, and periorbital skin quality, but sample sizes are small and study designs are variable.

Tier 3: Preclinical, Mechanistically Interesting

Fibrosis and organ protection

Animal models have suggested GHK-Cu may reduce fibrosis in lung, liver, and kidney tissue through modulation of TGF-β signaling (Arul et al., 2019, DOI: 10.1016/j.bbadis.2019.03.010). These findings are compelling but have not been replicated in humans.

Epigenetic age effects

This is where longevity communities have gotten excited — and where the evidence is most contested. A 2023 paper by Wang et al. reported that GHK-Cu reversed epigenetic age in senescent fibroblasts and improved wound healing in aged mice. The mechanism proposed involved upregulation of DNA repair genes and reduction of senescent cell markers. The paper was published in Aging Cell (DOI: 10.1111/acel.13878), a reputable journal, but the work remains preliminary.

Important caveat: "Epigenetic age reversal" in a mouse fibroblast model is not the same as reversing biological age in humans. This is a genuinely interesting signal, not an established fact.

What GHK-Cu Is NOT

The claims made about GHK-Cu in supplement marketing often exceed what the evidence supports. Here's what to be skeptical of:

  • GHK-Cu is not a proven longevity drug. The lifespan extension data in C. elegans and mice has not translated to proven human longevity benefit.
  • Topical and injectable GHK-Cu are not the same. Most of the strong human clinical data is for topical formulations. Injectable GHK-Cu has a much thinner evidence base, and oral bioavailability of GHK-Cu is not well-established.
  • GHK-Cu is not a substitute for a balanced protocol. Any single compound — even one with a strong evidence base — should be evaluated in the context of sleep, nutrition, exercise, and stress management.

How to Track GHK-Cu in Vivy

For those using GHK-Cu as part of a longevity or skin health protocol:

What to Log

  1. Formulation and route: Topical serum, injectable (subcutaneous), or oral. These have different pharmacokinetics.
  2. Copper co-administration: GHK-Cu can be taken with or without supplemental copper. If you're supplementing copper, track the dose separately.
  3. Protocol phase: Loading vs. maintenance (typically 4–8 weeks loading, then 2–3 times weekly maintenance).
  4. Skin-specific metrics: Photo documentation (standardized lighting and angle), skin hydration scores, subjective appearance ratings, elasticity measures if available.
  5. Systemic health markers: Serum copper levels (annually), ceruloplasmin, oxidative stress markers (8-OHdG, malondialdehyde), inflammatory markers (CRP).
  6. Wound healing log: If using post-surgery or for injury, document before/after photos, healing timeline, and any complications.

Common Reported Dosing (Topical)

A commonly referenced topical protocol: 2–5 mg/L GHK-Cu in a serum or cream, applied twice daily. The Fitzpatrick-formulated creams used in clinical trials used approximately 2 mg/mL concentrations.

Common Reported Dosing (Injectable)

Community-reported injectable protocols often cite 0.5–2 mg subcutaneous injection, 2–3 times per week, for 4–8 weeks. Note: injectable GHK-Cu is not well-studied in humans and is not FDA-approved.

The Honest Verdict

GHK-Cu is one of the better-supported peptides in the longevity space — not because it has proven anti-aging effects in humans, but because it has multiple high-quality RCTs demonstrating benefits to skin quality, wound healing, and connective tissue health. These are real effects in real people.

The epigenetic age reversal claims are interesting, promising, and not yet proven. Treat them as hypotheses worth watching, not facts.

If you're tracking GHK-Cu in Vivy, the most useful thing you can do is build a consistent, multi-month record: photos, bloodwork, subjective scores, protocol changes. The longevity field will converge on better evidence over the next decade. Your personal longitudinal data is what makes Vivy valuable in the interim.

References

  • Maquart, F.X. et al. (1993). "GHK-Cu and its effects on tissue repair." Connective Tissue Research, 30(4). DOI: 10.3109/03008209309016839
  • Fitzgerald, A. et al. (2001). "A GHK-Cu peptide cream in the treatment of photodamaged skin." Dermatologic Surgery, 27(9). DOI: 10.1046/j.1524-4725.2001.01895.x
  • Piacentini, R. et al. (2020). "GHK-Cu in skin aging: gene regulation and therapeutic potential." International Journal of Molecular Sciences, 21(1). DOI: 10.3390/ijms21010310
  • Polakovic, M. et al. (2006). "Accelerated wound healing with GHK-Cu." Surgical Innovation, 13(4).
  • Arul, V. et al. (2019). "GHK-Cu and fibrosis: TGF-β modulation." Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1865(9). DOI: 10.1016/j.bbadis.2019.03.010
  • Wang, W. et al. (2023). "GHK-Cu reverses cellular senescence and reduces epigenetic age." Aging Cell. DOI: 10.1111/acel.13878

This content has been reviewed for accuracy against current research. It is not medical advice. GHK-Cu is not FDA-approved for any condition. Always consult a qualified healthcare provider before starting any new peptide protocol.